As per recent research, tetrahydrocannabinol and cannabidiol can help you with spasticity, pain, and other multiple sclerosis symptoms. Nevertheless, better animal and human studies about THC and CBD for multiple sclerosis are essential for more conclusive findings.
Rana Zeine of Kean University and her colleagues looked at 28 animal and human studies about cannabidiol for MS symptoms. Then, they disclosed their discoveries through a post featured in the journal known as Biomedicines.
As per medical cannabis studies, add-on treatment with oromucosal spray blends with cannabidiol and tetrahydrocannabinol, is effective in improving measures of pain, spasticity as well as sleep- and bladder-related standard of life for MS patients.
While some advantages are maintained for over six to twelve months, others waned due to the prolonged consumption of the spray product with THC and cannabidiol for multiple sclerosis.
The increasing body of evidence with moderate quality about the effectiveness and safety of treatment with cannabidiol and tetrahydrocannabinol, has made some countries approve it for spasticity, bladder dysfunction and pain related to MS.
There are promising advantages of cannabis for neurologic symptom relief for people who suffer from movement disorders, such as Huntington’s disease and Parkinson’s disease.
Oral cannabidiol has been utilized to treat drug-resistant forms of seizures in kids having tuberous sclerosis diagnoses.
Four years ago, the Food and Drug Administration approved a cannabidiol item for seizures related to two rare types of epilepsy. However, to make people more confident about the effectiveness of medical cannabis as an additional therapy option for MS, there is a need for some forms of randomized controlled trials.
Scientists have to conduct further animal studies about how blending 1:1 cannabidiol and tetrahydrocannabinol will affect people as a multiple sclerosis treatment options. The study authors stated that there is solid evidence from pieces of animal research that better motor function and remyelination are possible.
Besides, a radiological study would be valuable as a follow-up measure to examine remyelination as precise relations have been found between MRI findings and different forms of CNS pathology in multiple sclerosis.
Zeine also stated that some participants withdraw from clinical studies as they lack benefits and are labeled non-responders. Zeine added that it may be since the healing process in the human brain takes a greater amount of time to form new myelin, neurons, mature oligodendrocytes and properly working synapses.